Chronic%20lymphocytic%20leukemia Treatment

Treatment

Surgical Intervention

Allogeneic Hematopoietic Cell Transplantation (HCT)

Should be considered in fit patients with high-risk chronic lymphocytic leukemia (CLL) who experience disease relapse 24-36 months after first-line therapy, or patients with refractory CLL
May be considered in patients without significant comorbidities with CLL refractory to small-molecule inhibitor therapy (eg Acalabrutinib, Duvelisib, Ibrutinib, Idelalisib, Venetoclax)
May be considered as part of a clinical trial for young patients with del(17p)/TP53 mutation with good performance status and minimal comorbidities
Reports showed an increase in the progression-free survival rate compared to those given chemotherapy alone
Allogeneic HCT is the preferred type of transplantation for CLL patients
- Provide long-term disease control as shown in several prospective studies
- Not recommended as a treatment option for relapsed/refractory CLL after initial therapy with purine-based regimen

Product Highlight - Cabometyx

29 Sep 2021

Cabozantinib 60 mg, 40 mg and 20 mg tab

Management of MDROs in the ICU and the role of newer antimicrobial agents

Prof. David Paterson, 30 Mar 2021

Intensive care unit (ICU) patients are at risk of developing serious infections with multidrug-resistant organisms (MDROs), which require appropriate and adequate antibiotic coverage. Early empirical coverage is pivotal in saving patients’ lives. At a recent webinar co-organized by the Society of Infectious Disease (Singapore) and Pfizer, renowned Professor David Paterson, Professor of Medicine and Director, The University of Queensland Centre for Clinical Research, and Consultant Infectious Diseases Physician, Royal Brisbane and Women’s Hospital, Brisbane, Australia, discussed the role of newer antimicrobial agents, including ceftazidime-avibactam (Zavicefta) in the management of MDROs in the ICU. Dr Wong Sin Yew, Infectious Disease Physician at Gleneagles Medical Centre and Mount Elizabeth Novena Specialist Centre, Singapore, chaired the event.

Product Highlight - Talzenna

13 Sep 2022

Talazoparib 0.25 mg hard cap